Kemin Pharma B.v.b.a.

Kemin Pharma Europe B.v.b.a.

Bart Ruttens

Benedikt J Sas

Johan Van Der Eycken

Johan Van Hemel

Jan Vandenkerckhove

Eric Peys

Petra Blom

Jan Balzarini

Eric De Clercq

Novel carbohydrate-based compounds with an attached ring system that have antimicrobial or cytostatic activity. The compounds are administered to humans and animals for the treatment or amelioration of bacterial, fungal, viral or protozoal infections or tumors. The compounds are of the general formula: 

Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity

The use of bicyclic carbohydrates for the treatment of parasite infections is described. Different bicyclic carbohydrates have been tested in vitro against a number of protozoa. These compounds also have been screened against viruses, tumors, bacteria and fungi. Compound A1, a thiophenyl-containing bicyclic carbohydrate possessed significant activity against, a parasite that causes the lethal sleeping sickness. Compound A2 and Compound A3, bicyclic carbohydrates with halogen containing aryl groups, possessed significant activity against, a parasite that causes leishmaniasis. Bicyclic carbohydrates in general, and Compound A1, Compound A2 and Compound A3 more specifically, could be possible treatments for the sleeping sickness and leishmaniasis in the future.

Bicyclic carbohydrates as antiprotozoal bioactive for the treatment of infections caused by parasites

We describe the use of bicyclic carbohydrates for the treatment of hepatitis C virus infections. Different bicyclic carbohydrates were tested in vitro against DNA-viruses, retro-viruses andsp., an important family of human and animal RNA pathogens. Significant activity was observed against the bovine viral diarrhea virus (BVDV). As pestiviruses, such as BVDV, share many similarities with hepatitis C virus (HCV), the bicyclic carbohydrates in general and the preferred bicyclic carbohydrates more specifically are expected to be a treatment for hepatitis C viral infections.

[object Object]

Bicyclic carbohydrates for the treatment of infections caused by herpseviridae, and in particular cytomegalovirus. The invention consists of the novel bicyclic carbohydrates the generic structure of which is: wherein Ris either -Bn or -Ph; Rand Rare either -alkyl, -aryl, -allyl, or &#x2014;H; Rand Rform a ring and are either &#x2014;CH(Ph)- or &#x2014;CH(aryl)- and X is either O, N or S.

Growing community of inventors

Ghent, Belgium

Bart Ruttens